OVAS - オバサイエンス （OvaScience Inc.） オバサイエンスOVASのチャート
OVASの企業情報
| symbol | OVAS |
|---|---|
| 会社名 | OvaScience Inc. （オバサイエンス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 OvaScience Inc. is a global fertility company. The Company is focused on the discovery development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation. オバサイエンスは米国のライフサイエンス企業。女性の生殖能力の向上に焦点をあて、不妊治療法の発見、開発、商業化を行う。同社の技術は卵巣の外側の層に見られる卵前駆細胞に基づいており、不妊治療用の卵子の人工培養のほか、サ―チュイン活性化物質によって卵巣機能を活性化させる研究を展開。本社はマサチュ―セッツ州。 OvaScience Inc is a part of the healthcare sector. Its core area of operation involves commercialization of new fertility treatments for women using its patented technology. |
| 本社所在地 | 9 4th Avenue Waltham MA 02451 USA |
| 代表者氏名 | Christopher A. Kroeger クリストファーA.クロガー |
| 代表者役職名 | Chief Executive Officer |
| 電話番号 | +1 617-500-2802 |
| 設立年月日 | 40634 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 36人 |
| url | www.ovascience.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ovas |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.11300 |
| 終値（lastsale） | 0.8078 |
| 時価総額（marketcap） | 28910359.0468 |
| 時価総額 | 時価総額（百万ドル） 28.63120 |
| 売上高 | 売上高（百万ドル） 0.29500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -24.99680 |
| 当期純利益 | 当期純利益（百万ドル） -32.96800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 OvaScience Inc revenues increased 1% to $148K. Net loss decreased 54% to $15.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative decrease of 62% to $6.9M (expense) Research and development decrease of 53% to $5M (expense) Loss from equity method investment decrease of 100% to $4K (expense). |
OVASのテクニカル分析
OVASのニュース
INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Acquisition Of OvaScience, Inc. Scheduled For A Shareholder Vote On December 4, 2018 - OVAS 2018-11-16 PR Newswire
NEW YORK , Nov. 16, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating OvaScience, Inc. ("OvaScience" or the "Company"…
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing 2018-11-01 Business Wire
New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million Current OvaScience Shareholders to Benefit from Improved Exchange Ratio OvaScience SM (Nasdaq:OVAS) and privately-held Millendo Therapeutics, Inc. , a cli…
INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Acquisition Of OvaScience, Inc. Scheduled For A Shareholder Vote On December 4, 2018 - OVAS 2018-11-16 PR Newswire
NEW YORK , Nov. 16, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating OvaScience, Inc. ("OvaScience" or the "Company"…
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing 2018-11-01 Business Wire
New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million Current OvaScience Shareholders to Benefit from Improved Exchange Ratio OvaScience SM (Nasdaq:OVAS) and privately-held Millendo Therapeutics, Inc. , a cli…
INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Acquisition Of OvaScience, Inc. Scheduled For A Shareholder Vote On December 4, 2018 - OVAS 2018-11-16 PR Newswire
NEW YORK , Nov. 16, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating OvaScience, Inc. ("OvaScience" or the "Company"…
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing 2018-11-01 Business Wire
New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million Current OvaScience Shareholders to Benefit from Improved Exchange Ratio OvaScience SM (Nasdaq:OVAS) and privately-held Millendo Therapeutics, Inc. , a cli…